Quick Facts

JumpStart

Chronic Wounds

A Global Problem Exacerbated by Biofilm

Up to 2% of the population in developed countries suffers from chronic wounds¹

6.7 million Americans 20 million worldwide

treated for chronic wounds per year²⁻³



Developed countries account for: **3%-5%** of total healthcare expenditures⁴

Type of Chronic Wound	Annual Treatment Cost (US)	Patient Cost per Wound
Pressure ulcers	>\$11 billion⁵	\$20,900 - \$151,700⁵
Diabetic foot ulcers	\$9 - \$13 billion⁵	\$50,000 ⁶
Venous ulcers	\$2.5 billion⁵	>\$34,0005

Pressure ulcers	31% - 79%7	Biofil direc closu wour wour
Diabetic foot ulcers	8% – 59% ⁸	
Venous ulcers	70% ³	

Biofilm infection may directly hinder wound closure or cause defective wound closure, leading to wound recurrence.⁵

Treat Chronic Wounds With JumpStart™ Dressing

Published studies demonstrate the ability of JumpStart dressing to:

- Kill a broad spectrum of microbes, including multidrugresistant and biofilm-forming bacteria⁹⁻¹¹
- Disrupt established biofilm infection¹²
- Prevent biofilm from forming¹²

arthrex.com ©2021 Arthrex, Inc. All rights reserved. LI1-000144-en-US_A

Biofilm Complicates Chronic Wounds



- ~78% of wounds are infected with bacterial biofilm¹³
- Key cause of delayed wound healing
- Shields the infection from patients' immune response and antibiotics⁵

Reference

1. Nusbaum SR, Carter MJ, Fife CE, et al. An economic evaluation of the impact, cost, and Medicare policy implications of chronic nonhealing wounds. *Value Health*. 2018;21(1):27-32. doi:10.1016/j.lyal.2017.07.007 2. Billions in global wound product sales, yet chronic wounds remain a chronic problem. based on new research from MedWarket Diligence, LLC. MedMarket Diligence, LLC. Accessed July 9, 2021. https://www.pr.com/ press-release?/49444.3. The chlanlenge. When was the last time you suit "outh". Wound Reach Foundation. Accessed July 9, 2021. https://www.woundreach.org/why-wounds/the-challenge 4. Jährbink K, Ni G, Sönnergen H, et al. The humanistic and economic burden of chronic wounds: a protocol for a systematic review. *Syst Rev*. 2017;6(1):15. doi:10.1186/s13643-016-0400-85. Sen CK. Human wounds and its burden: an updated compendium of estimates. *Adv Wound Care*. 2019;8(2):39-48. doi:10.1089/wound.2019.0946 G. Han G, Celley R. Chronic wound healing: a review of current management and treatments. *Adv Ther*. 2017;34(3):599-610. doi:10.1007/s1232:017-0478-y 7. Bruin Biometrics. Presure ulcer formation: patient populations at highest risk. 2013;1-7. 8. Lavery LA, Davis KE, Berriman SJ, et al. WHS guidelines update: diabetic foot ulcer treatment guidelines. *Wound Repair Regen*. 2016;24(1):112-12. 6. doi:10.1111/j vrr.12 391 9. Kim H, Makin I, Stilker J, et al. Antibacterial efficacy testing of a bioelectric wound dressing against clinical wound patogens. *Open Microbiol. J.* 2014;51:52. 1. doi:10.2114/18742856014001001. 10. Banerjee J, Ghatak P, Roy S, et al. Silker-zinc redox-coupled electroceutical wound dressing disrupts bacterial biofitm. *PLoS One*. 2015;24.15. doi:10.1371/journal.pone.0119531. 11. Kim H, Izadjoo M. Antibiofilm efficacy evaluation do a bioelectric dressing in mono- and multi-species biofilms. *J Wound Care*. 2015;24.524.50p1 2:510-514. doi:10.1097/SLA.000000000020526 13. Malone M, Bjarnsholt T, McBain AJ, et al. The prevalence of biofilms in chronic wounds: a systematic review and m

